GXHPC1

GXHPC1 is a novel autologous adipose-derived stem cell therapy for the treatment of liver cirrhosis (first-in-class). In pre-clinical research, we proved that GXHPC1 can ameliorate hepatic inflammation and reverse liver fibrosis.

According to the human trial phase I, the outcomes showed GXHPC1 did not cause any safety issue and show a tendency in improving liver function, indicating it possesses the potential for the treatment of liver cirrhosis (Ko-Chang Huang, 2019). Currently, GXHPC1 is ongoing in clinical trial phase II (NCT04088058).

Publication

SCI Journal

Article

Cell Transplantation

Dec. 2019

Adopting GXHPC1 for the Treatment of Liver Cirrhosis: Phase 1 Trial.

Cell Transplantation

May. 2017

Commercial Production of Autologous Stem Cells and Their Therapeutic Potential for Liver Cirrhosis.

Cell Transplantation

Feb. 2015

A Proposed Novel Stem Cell Therapy Protocol for Liver Cirrhosis.

Cell Transplantation

Feb. 2015

The Antisenescence Effect of Trans-Cinnamaldehyde on Adipose-Derived Stem Cells.

Journal of Neuroscience and Neuroengineering

Feb. 2013

Pre-Clinical Studies and Clinical Application of Adipose-Derived Stem Cells.

Cell Transplantation

Jul.
2012

Adipose-Derived Stem Cells Can Abrogate Chemical-Induced Liver Fibrosis and Facilitate Recovery of Liver Function.

Cell Transplantation

Jun. 2010

Transplantation of Human Wharton’s Jelly-Derived Stem Cells Alleviates Chemically Induced Liver Fibrosis in Rats.

Life Sciences

Sep. 2009

Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis.